NCT00463073View on ClinicalTrials.gov

Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Malignant Gliomas
Interventions
DRUG

Cetuximab

DRUG

Bevacizumab

DRUG

Irinotecan

Trial Locations (3)

2100

Rigshospitalet, Copenhagen

5000

Odense University Hospital, Odense

9000

Aalborg University Hospital, Aalborg

All Listed Sponsors
collaborator

Aalborg University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT00463073 - Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | Biotech Hunter | Biotech Hunter